MacrogenicsFRA:M55 +4.04%47 Days Payable is 43.15 as of Mar. 2026, which is 83% below its 10-year median of 251.75. GuruFocus rates FRA:M55 with a GF Score™ of 47/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 700 Biotechnology companies, Macrogenics ranks worse than 69% on this metric.
The historical rank and industry rank for Macrogenics's Days Payable or its related term are showing as below:
FRA:M55'
s Days Payable Range Over the Past 10 Years
Min: 47.81 Med: 251.75 Max: 1619.92
Current: 47.81
During the past 13 years, Macrogenics's highest Days Payable was 1619.92. The lowest was 47.81. And the median was 251.75.
FRA:M55's Days Payable is ranked worse than 69% of 700
companies
in the Biotechnology industry
Industry Median: 112.83
vs FRA:M55: 47.81
Macrogenics's Days Payable
declined
from Mar. 2025 (99.64) to Mar. 2026 (43.15).
It may suggest that Macrogenicsaccelerated paying its suppliers.
Macrogenics Days Payable Related Terms
Macrogenics Days Payable Historical Data
* Premium members only.
The historical data trend for Macrogenics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M55 vs IMRX, TRDA, SLNCF: Days Payable Comparison
For the Biotechnology subindustry, Macrogenics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's Days Payable distribution charts can be found below:
* The bar in red indicates where Macrogenics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Macrogenics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (FRA:M55) has a Days Payable of 43.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Macrogenics and its competitors. This is 83% below median its historical median of 251.75. Over the past decade, Macrogenics' Days Payable has ranged from 47.81 to 1,619.92. According to the industry distribution chart, Macrogenics ranks #483 out of 700 companies in the Biotechnology industry, placing it in the top 69%.
Is Macrogenics' Days Payable too high?
Macrogenics' current Days Payable of 43.15 is 83% below median its 10-year median of 251.75. Over the past 10 years, this metric has ranged from a low of 47.81 to a high of 1,619.92. The Biotechnology industry median Days Payable is 112.83. Macrogenics' value of 43.15 is 61.8% below this industry median. Based on the distribution chart, Macrogenics ranks #483 out of 700 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Days Payable compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #483 out of 700 companies for Days Payable. This places Macrogenics in the lower half of its industry. The industry median Days Payable is 112.83. Macrogenics' value of 43.15 is 61.8% below this benchmark. Historically, Macrogenics' own Days Payable has ranged from 47.81 to 1,619.92 over the past decade. While the company's 10-year median is 251.75 vs. the industry median of 112.83, Macrogenics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Macrogenics's current Days Payable of 43.15 is 61.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Macrogenics and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Days Payable is 43.15, which is 83% below median its own 10-year median of 251.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current Days Payable is 43.15, which is 83% below median its 10-year median of 251.75 and 61.8% below the Biotechnology industry median of 112.83. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Days Payable is 43.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for FRA:M55:
Days Payable: 43.15 (83% below median its 10-year median of 251.75)
GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
Industry Position: 61.8% below the Biotechnology median (#483 of 700)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score
Get the complete analysis for FRA:M55
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
